Status:
COMPLETED
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
Lead Sponsor:
University of Basrah
Conditions:
Type2diabetes
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospec...
Detailed Description
Despite the development of new drugs and therapeutic strategies for treating type 2 diabetes mellitus (T2DM), achieving long-term glycemic control remains a challenge. Results from the United Kingdom ...
Eligibility Criteria
Inclusion
- (must have)
- Newly diagnosed type 2 diabetes mellitus on no glucose-lowering drugs and
- Either hemoglobin A1c equal to or more than 9% and/or random blood glucose equal to or more than 300 mg/dl.
Exclusion
- Patients with type 1 diabetes mellitus,
- Urine ketone dipstick + and above at baseline or anytime throughout the study.
- Pregnancy.
- Current or recent steroid use.
- History of coronary heart disease and heart failure.
- GFR less than 60 mL/min/1.73 m2.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2024
Estimated Enrollment :
243 Patients enrolled
Trial Details
Trial ID
NCT06107153
Start Date
November 1 2023
End Date
November 1 2024
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faiha Specialized Diabetes, Endocrine, and Metabolism Center
Basra, Iraq, 61001